Mesothelioma: Pleural, Version 1.2024
James Stevenson, David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm M. DeCamp, Aakash Desai, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, Marina Chiara Garassino, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Gregory A. Otterson, Dawn Owen, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan W. Riess, Theresa A. Shapiro, Aditi P. Singh, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Lisa Hang
Abstract
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.